# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000886163-16-000165
Filing Date
2016-04-12
Accepted
2016-04-12 16:05:04
Documents
5
Effectiveness Date
2016-04-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | lgndproxynoticedoc.htm | DEFA14A | 27538
2 |  | a02bfceligandpharmacommo001.jpg | GRAPHIC | 229336
3 |  | a02bfceligandpharmacommo002.jpg | GRAPHIC | 102572
4 |  | a02bffbligandpharmanotic001.jpg | GRAPHIC | 207587
5 |  | a02bffbligandpharmanotic002.jpg | GRAPHIC | 168504
| Complete submission text file | 0000886163-16-000165.txt |  | 991070

Mailing Address 11119 NORTH TORREY PINES ROAD SUITE 200 LA JOLLA CA 92037
Business Address 11119 NORTH TORREY PINES ROAD SUITE 200 LA JOLLA CA 92037 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33093 | Film No.: 161567302
SIC: 2834 Pharmaceutical Preparations